INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Skolnik, MD
Inovio Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Stanford University, School of Medicine
Palo Alto, California, United States
- University of California, San Francisco
San Francisco, California, United States
- University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory University School of Medicine
Atlanta, Georgia, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Henry Ford Health System
Detroit, Michigan, United States
- Rutgers University - Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Columbia University Medical Center the Neurological Institute of New York
New York, New York, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- New York University Langone Medical Center; Perlmutter Cancer Center
New York, New York, United States
- New York-Presbyterian Hospital/weill Cornell Medical Center
New York, New York, United States
- University of North Carolina School of Medicine
Chapel Hill, North Carolina, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Oregon Health & Science University
Portland, Oregon, United States
- University of Pennsylvania Health System: Penn Medicine
Philadelphia, Pennsylvania, United States
- Upmc Cancer Center Neuro-Oncology; Upmc Cancer Pavilion
Pittsburgh, Pennsylvania, United States
- Texas Oncology
Austin, Texas, United States
- Baylor College of Medicine
Houston, Texas, United States
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2018
- Primary completion
- 31 Dec 2026
- Completion
- 31 Dec 2026
- Last update posted
- 4 May 2026
- Registered enrollment
- 52
- Registry id
- NCT03491683
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.